S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Outlook Therapeutics Stock Price, News & Analysis (NASDAQ:OTLK)

$1.26
-0.07 (-5.26 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$1.25
Now: $1.26
$1.33
50-Day Range
$1.26
MA: $1.50
$1.81
52-Week Range
$0.85
Now: $1.26
$10.96
Volume99,381 shs
Average Volume1.84 million shs
Market Capitalization$35.57 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.64
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTLK
CUSIPN/A
CIKN/A
Phone609-619-3990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 million
Book Value($2.83) per share

Profitability

Net Income$-30,090,000.00
Net Margins-1,197.32%

Miscellaneous

Employees56
Market Cap$35.57 million
Next Earnings Date12/17/2019 (Estimated)
OptionableNot Optionable

Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.


Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics shares reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.13. The firm had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.73 million. View Outlook Therapeutics' Earnings History.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, December 17th 2019. View Earnings Estimates for Outlook Therapeutics.

What price target have analysts set for OTLK?

5 brokerages have issued 12-month price objectives for Outlook Therapeutics' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Outlook Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 614.3% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.

What is the consensus analysts' recommendation for Outlook Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.

Has Outlook Therapeutics been receiving favorable news coverage?

Headlines about OTLK stock have trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Outlook Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Outlook Therapeutics.

Who are some of Outlook Therapeutics' key competitors?

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Big 5 Sporting Goods (BGFV), Lockheed Martin (LMT), Avon Products (AVP), Biocept (BIOC), Insys Therapeutics (INSY), Canopy Growth (CGC), New Age Beverages (NBEV), NVIDIA (NVDA), Aphria (APHA) and CVS Health (CVS).

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the folowing people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
  • Dr. Pankaj Mohan, Founder & Director (Age 54)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
  • Mr. Terry Dagnon, Chief Operating Officer (Age 57)
  • Rick Gregory, Director of Marketing & Communications

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $1.26.

How big of a company is Outlook Therapeutics?

Outlook Therapeutics has a market capitalization of $35.57 million and generates $3.09 million in revenue each year. The company earns $-30,090,000.00 in net income (profit) each year or ($10.80) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.View Additional Information About Outlook Therapeutics.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is http://www.outlooktherapeutics.com/.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel